A database of FDA approved therapeutic peptides and proteins
| This page displays user query in tabular form. |
Th1236 details |
| Primary information | |
|---|---|
| ID | 1848 |
| ThPP ID | Th1236 |
| Therapeutic Peptide/Protein Name | Sipuleucel-T |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | IIIc |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | NA |
| Description | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared specifically for each patient. In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data). Sipuleucel-T is marketed under the brand name Provenge by Dendreon Corporation. Sipuleucel-T was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC). The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014. |
| Indication/Disease | Sipuleucel-T is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. |
| Pharmacodynamics | NA |
| Mechanism of Action | Sipuleucel-T is designed to induce an immune response targeted against PAP, an antigen expressed in most prostate cancers. During ex vivo culture with PAP-GM-CSF, APCs take up and process the recombinant target antigen into small peptides that are then displayed on the APC surface. The precise mechanism remains unknown, however. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| Volume of Distribution | NA |
| Clearance | NA |
| Categories | Antineoplastic and Immunomodulating Agents |
| Patents Number | US8153120 |
| Date of Issue | 22/03/07 |
| Date of Expiry | 22/03/27 |
| Drug Interaction | The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with 2-Methoxyethanol, 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine, Abatacept, abetimus, ABR-215757, Acteoside, Adalimumab, Adefovir Dipivoxil, Afelimomab, Alefacept. |
| Target | Prostatic acid phosphatase |
| Information of corresponding available drug in the market | |
| Brand Name | Provenge |
| Company | NA |
| Brand Discription | Provenge (sipuleucel-T) contains a protein that stimulates the body's immune system to help it respond against certain cancer cells. |
| Prescribed for | Provenge® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer |
| Chemical Name | NA |
| Formulation | NA |
| Physcial Appearance | Solution |
| Route of Administration | Intravenous |
| Recommended Dosage | The recommended course of therapy for PROVENGE is 3 complete doses, given at approximately 2-week intervals. In controlled clinical trials, the median dosing interval between infusions was 2 weeks (range 1 to 15 weeks); the maximum dosing interval has not been established |
| Contraindication | Hypersensitivity to the active substance |
| Side Effects | fever;gredness, swelling, oozing, or other signs of infection where the IV needle was placed; orgsigns of infection around the veins your cells were collected from. |
| Useful Link | http://www.rxlist.com/provenge-drug.htm , http://www.drugs.com/pro/provenge.html , https://www.cancer.gov/about-cancer/treatment/drugs/fda-sipuleucel-T |
| PubMed ID | 16752945, 26025563, 15176049, 16736512 |
| 3-D Structure | N.A. |